Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock (BGMSP) Stock Forecast & Analysis
Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock (BGMSP:NASDAQ), powered by AI.
- Current Price
- $0.70
- Sector
- Healthcare
What is the Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock stock price forecast?
Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock is currently trading at $0.70. View real-time AI analysis on Alpha Lenz.
What is Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock insider trading activity?
View the latest insider trading data for Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock on Alpha Lenz.
What is Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock's P/E ratio?
View Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock's valuation metrics on Alpha Lenz.
Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock
NASDAQ · BGMSP“Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock's ROE is -128.4%. Explore profitability and growth together.”
Ask for details →Company Overview
Bio Green Med Solution, Inc. engages in the distributing, trading, and installation of protective and fire safety materials and equipment, and fire protection and prevention systems. It also researches and develops pharmaceuticals. The company was formerly known as Cyclacel Pharmaceuticals, Inc. and changed its name to Bio Green Med Solution, Inc. in September 2022. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.
Company Statistics
FY 2025Profile
Margins
Valuation
Growth (CAGR)
Returns
Financial Health
“Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock's ROE is -128.4%. Explore profitability and growth together.”
Ask for details →Frequently Asked Questions
Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock (ticker: BGMSP) is a company listed on NASDAQ in the Healthcare sector (Biotechnology).
The current price is $0.7 with a P/E ratio of -x and P/B of -x.
ROE is -128.45% and operating margin is -1128.11%. Annual revenue is $747,000.